| Characteristic . | Overall . | BJI . | cUTI . | RTI . | IAI . | cSSTI . | Bacteremia . |
|---|---|---|---|---|---|---|---|
| (n = 126), No. (%) . | (n = 34), No. (%) . | (n = 29), No. (%) . | (n = 23), No. (%) . | (n = 20), No. (%) . | (n = 17), No. (%) . | (n = 3), No. (%) . | |
| OPAT duration, median (IQR), d | 21 (14–38) | 39 (26–42) | 14 (8–17) | 21 (14–29) | 21 (14–22) | 26 (19–54) | 41 (28–44) |
| C/T dosage per day, median (range) | 4.5 (1.125–9.0) | 4.5 (2.25–9.0) | 4.5 (2.25–4.5) | 4.5 (2.25–9.0) | 4.5 (1.125–4.5) | 4.5 (2.25–4.5) | 4.5 (1.125–9.0) |
| <4.5 g | 23 (18) | 5 (15) | 10 (34) | 2 (9) | 2 (10) | 3 (18) | 1 (33) |
| >4.5 g | 7 (6) | 3 (9) | … | 3 (13) | … | … | 1 (33) |
| Frequency of infusion | … | ||||||
| Intermittent | 123 (98) | 33 (97) | 29 (100) | 23 (100) | 20 (100) | 16 (94) | 2 (67) |
| Continuous | 3 (2) | 1 (3) | … | … | … | 1 (6) | 1 (33) |
| Method of administration | … | ||||||
| Elastomeric pump, self-administration at home | 83 (66) | 28 (82) | 14 (48) | 10 (43) | 16 (80) | 13 (76) | 2 (67) |
| Ambulatory pump, daily pump bag changes in OIC | 42 (33) | 6 (18) | 14 (48) | 13 (57) | 4 (20) | 4 (24) | 1 (33) |
| Stationary pump, daily administration in OIC | 1 (1) | … | … | … | … | … | … |
| Concomitant intravenous antibiotic therapy | 16 (13) | 9 (26) | 1 (3) | 1 (4) | … | 5 (29) | … |
| Characteristic . | Overall . | BJI . | cUTI . | RTI . | IAI . | cSSTI . | Bacteremia . |
|---|---|---|---|---|---|---|---|
| (n = 126), No. (%) . | (n = 34), No. (%) . | (n = 29), No. (%) . | (n = 23), No. (%) . | (n = 20), No. (%) . | (n = 17), No. (%) . | (n = 3), No. (%) . | |
| OPAT duration, median (IQR), d | 21 (14–38) | 39 (26–42) | 14 (8–17) | 21 (14–29) | 21 (14–22) | 26 (19–54) | 41 (28–44) |
| C/T dosage per day, median (range) | 4.5 (1.125–9.0) | 4.5 (2.25–9.0) | 4.5 (2.25–4.5) | 4.5 (2.25–9.0) | 4.5 (1.125–4.5) | 4.5 (2.25–4.5) | 4.5 (1.125–9.0) |
| <4.5 g | 23 (18) | 5 (15) | 10 (34) | 2 (9) | 2 (10) | 3 (18) | 1 (33) |
| >4.5 g | 7 (6) | 3 (9) | … | 3 (13) | … | … | 1 (33) |
| Frequency of infusion | … | ||||||
| Intermittent | 123 (98) | 33 (97) | 29 (100) | 23 (100) | 20 (100) | 16 (94) | 2 (67) |
| Continuous | 3 (2) | 1 (3) | … | … | … | 1 (6) | 1 (33) |
| Method of administration | … | ||||||
| Elastomeric pump, self-administration at home | 83 (66) | 28 (82) | 14 (48) | 10 (43) | 16 (80) | 13 (76) | 2 (67) |
| Ambulatory pump, daily pump bag changes in OIC | 42 (33) | 6 (18) | 14 (48) | 13 (57) | 4 (20) | 4 (24) | 1 (33) |
| Stationary pump, daily administration in OIC | 1 (1) | … | … | … | … | … | … |
| Concomitant intravenous antibiotic therapy | 16 (13) | 9 (26) | 1 (3) | 1 (4) | … | 5 (29) | … |
Abbreviations: C/T, ceftolozane/tazobactam; IQR, interquartile range; OIC, physician office infusion center; OPAT, outpatient antimicrobial therapy.
Values are expressed as number of patients (%), unless otherwise indicated.
Daptomycin (n = 10), vancomycin (n = 5), televancin (n = 1).
| Characteristic . | Overall . | BJI . | cUTI . | RTI . | IAI . | cSSTI . | Bacteremia . |
|---|---|---|---|---|---|---|---|
| (n = 126), No. (%) . | (n = 34), No. (%) . | (n = 29), No. (%) . | (n = 23), No. (%) . | (n = 20), No. (%) . | (n = 17), No. (%) . | (n = 3), No. (%) . | |
| OPAT duration, median (IQR), d | 21 (14–38) | 39 (26–42) | 14 (8–17) | 21 (14–29) | 21 (14–22) | 26 (19–54) | 41 (28–44) |
| C/T dosage per day, median (range) | 4.5 (1.125–9.0) | 4.5 (2.25–9.0) | 4.5 (2.25–4.5) | 4.5 (2.25–9.0) | 4.5 (1.125–4.5) | 4.5 (2.25–4.5) | 4.5 (1.125–9.0) |
| <4.5 g | 23 (18) | 5 (15) | 10 (34) | 2 (9) | 2 (10) | 3 (18) | 1 (33) |
| >4.5 g | 7 (6) | 3 (9) | … | 3 (13) | … | … | 1 (33) |
| Frequency of infusion | … | ||||||
| Intermittent | 123 (98) | 33 (97) | 29 (100) | 23 (100) | 20 (100) | 16 (94) | 2 (67) |
| Continuous | 3 (2) | 1 (3) | … | … | … | 1 (6) | 1 (33) |
| Method of administration | … | ||||||
| Elastomeric pump, self-administration at home | 83 (66) | 28 (82) | 14 (48) | 10 (43) | 16 (80) | 13 (76) | 2 (67) |
| Ambulatory pump, daily pump bag changes in OIC | 42 (33) | 6 (18) | 14 (48) | 13 (57) | 4 (20) | 4 (24) | 1 (33) |
| Stationary pump, daily administration in OIC | 1 (1) | … | … | … | … | … | … |
| Concomitant intravenous antibiotic therapy | 16 (13) | 9 (26) | 1 (3) | 1 (4) | … | 5 (29) | … |
| Characteristic . | Overall . | BJI . | cUTI . | RTI . | IAI . | cSSTI . | Bacteremia . |
|---|---|---|---|---|---|---|---|
| (n = 126), No. (%) . | (n = 34), No. (%) . | (n = 29), No. (%) . | (n = 23), No. (%) . | (n = 20), No. (%) . | (n = 17), No. (%) . | (n = 3), No. (%) . | |
| OPAT duration, median (IQR), d | 21 (14–38) | 39 (26–42) | 14 (8–17) | 21 (14–29) | 21 (14–22) | 26 (19–54) | 41 (28–44) |
| C/T dosage per day, median (range) | 4.5 (1.125–9.0) | 4.5 (2.25–9.0) | 4.5 (2.25–4.5) | 4.5 (2.25–9.0) | 4.5 (1.125–4.5) | 4.5 (2.25–4.5) | 4.5 (1.125–9.0) |
| <4.5 g | 23 (18) | 5 (15) | 10 (34) | 2 (9) | 2 (10) | 3 (18) | 1 (33) |
| >4.5 g | 7 (6) | 3 (9) | … | 3 (13) | … | … | 1 (33) |
| Frequency of infusion | … | ||||||
| Intermittent | 123 (98) | 33 (97) | 29 (100) | 23 (100) | 20 (100) | 16 (94) | 2 (67) |
| Continuous | 3 (2) | 1 (3) | … | … | … | 1 (6) | 1 (33) |
| Method of administration | … | ||||||
| Elastomeric pump, self-administration at home | 83 (66) | 28 (82) | 14 (48) | 10 (43) | 16 (80) | 13 (76) | 2 (67) |
| Ambulatory pump, daily pump bag changes in OIC | 42 (33) | 6 (18) | 14 (48) | 13 (57) | 4 (20) | 4 (24) | 1 (33) |
| Stationary pump, daily administration in OIC | 1 (1) | … | … | … | … | … | … |
| Concomitant intravenous antibiotic therapy | 16 (13) | 9 (26) | 1 (3) | 1 (4) | … | 5 (29) | … |
Abbreviations: C/T, ceftolozane/tazobactam; IQR, interquartile range; OIC, physician office infusion center; OPAT, outpatient antimicrobial therapy.
Values are expressed as number of patients (%), unless otherwise indicated.
Daptomycin (n = 10), vancomycin (n = 5), televancin (n = 1).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
